[1] |
Cao H, Parikh TN, Zheng J. Amyopathic dermatomyositis or dermatomyositis⁃like skin disease: retrospective review of 16 cases with amyopathic dermatomyositis[J]. Clin Rheumatol, 2009,28(8):979⁃984. doi: 10.1007/s10067⁃009⁃1152⁃9.
|
[2] |
Peloro TM, Miller OF 3rd, Hahn TF, et al. Juvenile dermatomyositis: a retrospective review of a 30⁃year experience[J]. J Am Acad Dermatol, 2001,45(1):28⁃34. doi: 10.1067/mjd.2001.113686.
|
[3] |
Shirani Z, Kucenic MJ, Carroll CL, et al. Pruritus in adult dermatomyositis[J]. Clin Exp Dermatol, 2004,29(3):273⁃276. doi: 10.1111/j.1365⁃2230.2004.01510.x.
|
[4] |
Kleitsch J, Weiner JD, Pandya R, et al. The physical and emotional impact of cutaneous dermatomyositis: a qualitative study[J]. Arch Dermatol Res, 2023,315(8):2431⁃2435. doi: 10.1007/s00403⁃023⁃02625⁃2.
|
[5] |
Rochman Y, Kashyap M, Robinson GW, et al. Thymic stromal lymphopoietin⁃mediated STAT5 phosphorylation via kinases JAK1 and JAK2 reveals a key difference from IL⁃7⁃induced signaling[J]. Proc Natl Acad Sci U S A, 2010,107(45):19455⁃19460. doi: 10.1073/pnas.1008271107.
|
[6] |
Wilson SR, Thé L, Batia LM, et al. The epithelial cell⁃derived atopic dermatitis cytokine TSLP activates neurons to induce itch[J]. Cell, 2013,155(2):285⁃295. doi: 10.1016/j.cell.2013.08.057.
|
[7] |
Lee JU, Chang HS, Lee HJ, et al. Upregulation of interleukin⁃33 and thymic stromal lymphopoietin levels in the lungs of idiopathic pulmonary fibrosis[J]. BMC Pulm Med, 2017,17(1):39. doi: 10.1186/s12890⁃017⁃0380⁃z.
|
[8] |
Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts)[J]. N Engl J Med, 1975,292(7):344⁃347. doi: 10. 1056/NEJM197502132920706.
|
[9] |
Sontheimer RD. Cutaneous features of classic dermatomyositis and amyopathic dermatomyositis[J]. Curr Opin Rheumatol, 1999,11(6):475⁃482.
|
[10] |
Ono N, Kai K, Maruyama A, et al. The relationship between type 1 IFN and vasculopathy in anti⁃MDA5 antibody⁃positive dermatomyositis patients[J]. Rheumatology (Oxford), 2019,58(5):786⁃791. doi: 10.1093/rheumatology/key386.
|
[11] |
Truchetet ME, Demoures B, Eduardo Guimaraes J, et al. Platelets induce thymic stromal lymphopoietin production by endothelial cells: contribution to fibrosis in human systemic sclerosis[J]. Arthritis Rheumatol, 2016,68(11):2784⁃2794. doi: 10.1002/art.39817.
|
[12] |
Fiorentino DF, Kuo K, Chung L, et al. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor⁃1γ antibodies in adults with dermatomyositis[J]. J Am Acad Dermatol, 2015,72(3):449⁃455. doi: 10.1016/j.jaad.2014.12. 009.
|
[13] |
Menzies⁃Gow A, Corren J, Bourdin A, et al. Tezepelumab in adults and adolescents with severe, uncontrolled asthma[J]. N Engl J Med, 2021,384(19):1800⁃1809. doi: 10.1056/NEJMoa 2034975.
|
[14] |
Wang W, Li Y, Lv Z, et al. Bronchial allergen challenge of patients with atopic asthma triggers an alarmin (IL⁃33, TSLP, and IL⁃25) response in the airways epithelium and submucosa[J]. J Immunol, 2018,201(8):2221⁃2231. doi: 10.4049/jimmunol. 1800709.
|
[15] |
Chen M, Quan C, Diao L, et al. Measurement of cytokines and chemokines and association with clinical severity of dermatomyositis and clinically amyopathic dermatomyositis[J]. Br J Dermatol, 2018,179(6):1334⁃1341. doi: 10.1111/bjd.17079.
|
[16] |
Miyagaki T, Sugaya M, Fujita H, et al. Increased serum thymic stromal lymphopoietin levels in patients with cutaneous T cell lymphoma[J]. Clin Exp Dermatol, 2009,34(4):539⁃540. doi: 10.1111/j.1365⁃2230.2008.02990.x.
|
[17] |
Luo J, Zhu Z, Zhai Y, et al. The role of TSLP in atopic dermatitis: from pathogenetic molecule to therapeutical target[J]. Mediators Inflamm, 2023,2023:7697699. doi: 10.1155/2023/7697699.
|
[18] |
Zhao Q, Zhu Z, Fu Q, et al. Baricitinib for the treatment of cutaneous dermatomyositis: a prospective, open⁃label study[J]. J Am Acad Dermatol, 2022,87(6):1374⁃1376. doi: 10.1016/j.jaad.2022.08.025.
|
[19] |
Kim HJ, Zeidi M, Bonciani D, et al. Itch in dermatomyositis: the role of increased skin interleukin⁃31[J]. Br J Dermatol, 2018,179(3):669⁃678. doi: 10.1111/bjd.16498.
|
[20] |
Werth VP, Hejazi E, Pena SM, et al. Safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in patients with dermatomyositis with refractory skin disease: a randomized clinical trial[J]. J Invest Dermatol, 2022,142(10):2651⁃2659.e1. doi: 10.1016/j.jid.2022.03.029.
|
[21] |
Ahn SS, Yeo H, Jung E, et al. β⁃Caryophyllene ameliorates 2,4⁃dinitrochlorobenzene⁃induced atopic dermatitis through the downregulation of mitogen⁃activated protein kinase/EGR1/TSLP signaling axis[J]. Int J Mol Sci, 2022,23(23):14861. doi: 10. 3390/ijms232314861.
|